Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Somnus Therapeutics Inc.

www.somnusthera.com

Latest From Somnus Therapeutics Inc.

Start-Up Previews

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Antibiotics Start-Ups," features profiles of Indel Therapeutics, MicuRx Pharmaceuticals and Trius Therapeutics. Plus these Start-Ups Across Health Care: DFine, NexeonMedSystems, SmartCells and Somnus Therapeutics.

Somnus Therapeutics Inc.

Somnus Therapeutics is developing a timed-release formulation of zaleplon, a GABA agonist that is currently approved for short-term difficulty in falling asleep. According to company, its version of the drug is expected to offer patients an initial two hours of drug-free delta sleep, followed by the controlled release of a short-acting active ingredient, which may allow people to awaken more refreshed and alert.
BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Somnus Therapeutics Inc.
  • Senior Management
  • Gary Cupit, PharmD, CEO
    Daniel, Jr. Cabo, CFO
    Mary Osbakken, MD, PhD, CMO
    Linda Hogan, CBO
  • Contact Info
  • Somnus Therapeutics Inc.
    Phone: (908) 901-0300
    135 Route 202/206
    Bedminster, NJ 07921
    USA
UsernamePublicRestriction

Register